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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A392Analogue Scale (VAS), and the Range of Motion (ROM) was measured
using a digital goniometer. The Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) and ascending-descending
stairs time were used to assess function.
Results:Mean age and body mass index (BMI) of our study group were,
respectively, 54.7±6.8 years and 31.3±5.1 kg/m2 in the MWM group and
54.6±7.3 years and 30.5±4.2 kg/m2 in the PJM group. There was no
signiﬁcant difference between groups in respect of age and BMI
(p>0.05). Both groups had signiﬁcant decreases in pain according to the
VAS (p<0.05). The ROM values and function level signiﬁcantly improved
within both groups (p<0.05). There was no statistically signiﬁcant dif-
ference in pain (p¼0.13), knee ﬂexion (p¼0.77), knee extension ROM
(p¼0.43), WOMAC scores (p¼0.65) and ascending-descending stairs
time (p¼0.06) between the two groups before and after the treatment.
Conclusions: The results indicate that patients with osteoarthritis of
the knee gain clinically beneﬁt from mobilization techniques on pain,
ROM and function. Therefore, we suggest that physiotherapist either
can apply MWM or PJM techniques based on their clinical experience in
the management of osteoarthritis of the knee. This work was supported
by University, Scientiﬁc Research Projects (Number:30150)
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EFFECTS OF 8-WEEK WHOLE-BODY VIBRATION TRAINING ON KNEE
EXTENSORS STRENGTH IN HEALTHY YOUNG VOLUNTEERS
S. Esmaeilzadeh, M. Akpinar, S.E. Polat, A. Yildiz, A. Oral. Istanbul Univ.
Istanbul Faculty of Medicine, Istanbul, Turkey
Purpose: Knee extensor muscle weakness increases the risk of different
knee disorders including knee osteoarthritis. The aim of present study
was to determine the effects of 8 weeks whole-body vibration training
(WBVT) program on the strength of knee extensor muscles in untrained
volunteers.
Methods: Twenty eligible healthy untrained youngwomen volunteered
to participate in a supervised 8 weeks WBVT program that consisted of
24 sessions on vibration platform (30- Hz, 2-6 mm, 2-3 positions, 2-24
sets) three times per week for 8 weeks. Isometric and dynamic strength
of the knee extensor muscles were measured prior to and at the end of
the 8-week training.
Results: There was a signiﬁcant increase in the maximal voluntary
isometric contraction (p¼0.046) at the end of the 8-week training. In
addition, both concentric (p¼0.004) and eccentric (p¼0.031) peak tor-
ques of knee extensors increased signiﬁcantly after 8 weeks training.
Conclusions: These results suggest that 8 weeks WBVT is an effective
training method for improving the strength knee extensors in young
healthy women.
Therapy: Pharmacologic
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INTRA-ARTICULAR CORTICOSTEROIDS MAY BE A COST-EFFECTIVE
STRATEGY FOR SHORT-TERM MANAGEMENT OF KNEE
OSTEOARTHRITIS
R.R. Bannuru y, J.B. Wong y, D.M. Kent y, C.H. Schmid z, T.E. McAlindon y.
y Tufts Med. Ctr., Boston, MA, USA; zBrown Univ., Providence, RI, USATable 1
Model Inputs
Acetaminophen Diclofenac Ibuprofen
Dosage (mg/day) 3000 150 2400
Total WOMAC Change
from Baseline* [95% CrI]
16.07
[13.68-18.46]
22.7
[20.04-25.36]
21.17
[18.42-23.92]
Total Cost (USD)/3 mo [SD] 33.33 [8.65] 268.64 [59.15] 117.32 [27.47]
3-month Adverse Event
Probabilities (%) [SD]
GI Distress 14.46 [0.54] 24.05 [0.90] 14.46 [0.54]
Symptomatic Ulcer 0.07 [0.03] 0.14 [0.02] 0.20 [0.09]
Complicated Ulcer 0.03 [0.02] 0.07 [0.01] 0.08 [0.04]
Myocardial Infarction 0.07 [0.03] 0.09 [0.01] 0.15 [0.11]
Stroke 0.03 [0.02] 0.06 [0.01] 0.06 [0.04]
Local Joint Reaction 0 0 0
Septic Joint 0 0 0
IA ¼ intra-articular; inj ¼ injection; 3 mo ¼ 3 month; WOMAC ¼ Western Ontario and
dollar; GI ¼ gastrointestinal; * Baseline total WOMAC score ¼ 51.17 (15.19).Purpose: The most commonly prescribed treatments for knee osteo-
arthritis (OA) are traditional nonsteroidal anti-inﬂammatory drugs
(NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors. The gastro-
intestinal (GI) and cardiovascular (CV) adverse events associated with
these agents have important quality of life and resource use implica-
tions. While most prior evaluations have compared the use of tradi-
tional NSAIDs with COX-2 inhibitors, none has included injection
therapies such as corticosteroids and hyaluronic acid. Commonly used
injection therapies are relatively free of the GI and CV adverse events
commonly seen with the use of oral therapies. However, since the costs
of some injection therapies are relatively high compared with tradi-
tional NSAIDs, it is unclear whether these treatments are cost-effective.
Therefore, we performed a cost-effectiveness analysis comparing vari-
ous oral and intra-articular (IA) injection therapies for OA over a period
of three months.
Methods: We conducted an economic evaluation using a decision
analytic model (Figure 1). Estimates of cardiovascular (CV) and gas-
trointestinal (GI) adverse events were based on data from three large
pivotal safety trials, and observational data were used for sensitivity
analyses. Treatment efﬁcacy was estimated by performing a network
meta-analysis of the 77 trials reporting total Western Ontario and
McMaster Universities (WOMAC) osteoarthritis index score for these
interventions. Other model inputs were obtained from the relevant
literature (Table 1). The base-case model was run for a hypothetical
patient population with moderate knee OA aged between 55-64 years
with no previous history of GI or CV adverse events. Analyses were
conducted in a high-risk model consisting of patients aged between 65-
74 years who are at a high risk of GI or CV adverse events. We compared
commonly used treatments for which suitable data were available;
these included acetaminophen (3000 mg/day), diclofenac (150 mg/
day), ibuprofen (2400 mg/day), naproxen (1000 mg/day), celecoxib
(200 mg/day), IA corticosteroids, & IA hyaluronic acid (both single
course). The possibility of adding a proton pump inhibitor (PPI) (ome-
prazole 20 mg/day) was also tested. Main outcome measures were
direct costs, quality-adjusted life-years (QALY) gained and incremental
cost-effectiveness ratios (ICER). QALYs were calculated from pooled
estimates of efﬁcacy and major adverse events (i.e. GI distress, symp-
tomatic and complicated ulcer, myocardial infarction, stroke, local joint
reactions, and septic joint).
Results: Our base case analysis showed that IA corticosteroids were the
preferred strategy for a willingness to pay threshold of $3,000 (Table 2;
Figure 2). If a decision maker is willing to pay $25,000, ibuprofen þ PPI
strategy was cost-effective. NSAIDs without PPI co-prescription were
dominated by NSAIDs with PPI (more expensive and less effective).
Compared to the base-case model, the high-risk model featured more
serious adverse events leading to a greater impact on quality of life. This
increase in risk did not change the relative rankings of treatments
compared to the base-case, although the willingness to pay thresholds
increased marginally. NSAIDs without PPI co-prescription were still
dominated in the high-risk model. In both models, we found that it will
cost less than $10,000 to gain a QALY by adding PPIs to NSAIDs.
Conclusions: For a willingness to pay threshold of $3,000, IA cortico-
steroids are the preferred strategy for managing knee OA over a 3-
month period. This result is driven primarily by their substantial efﬁ-
cacy (at least in the short-term) and relatively high level of safety. OurNaproxen Celecoxib IA Corticosteroids IA Hyaluronic Acid
1000 200 1 inj/3 mo 1-5 inj/3 mo
21.35
[19.47-23.23]
19.68
[18.13-21.23]
18.24
[12.43-24.05]
23.73
[18.90-28.56]
241.24 [48.26] 758.12 [100.00] 56.88 [11.00] 1358.47 [105.47]
17.00 [0.43] 14.16 [0.46] 7.52 [0.25] 7.52 [0.25]
0.28 [0.07] 0.09 [0.04] 0.04 [0.02] 0.04 [0.02]
0.07 [0.02] 0.05 [0.03] 0.2 [0.01] 0.2 [0.01]
0.06 [0.03] 0.15 [0.10] 0.06 [0.03] 0.06 [0.03]
0.08 [0.03] 0.03 [0.02] 0.2 [0.01] 0.2 [0.01]
0 0 8.51 [0.87] 13.09 [0.46]
0 0 0.002 [0.001] 0.002 [0.001]
McMaster Universities Arthritis Index; CrI ¼ credible interval; USD ¼ United States
